{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:10:46Z","timestamp":1788876646148,"version":"build-2803163510"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR069544, RS-2022-NR071965, RS-2025-24873009"],"award-info":[{"award-number":["RS-2022-NR069544, RS-2022-NR071965, RS-2025-24873009"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Athymic mice are widely used in preclinical research to study tumor growth, metastasis, and the efficacy of conventional and targeted therapies. However, these animals are profoundly deficient in thymus-derived conventional T cells while retaining B cells and substantial innate immune function, creating a selective blind spot for treatment effects that require adaptive immune amplification. In addition, many modern chemotherapeutic agents act beyond direct tumor-cell-intrinsic cytotoxicity, relying instead on immunogenic cell death (ICD), antigen presentation, and host immune amplification. An intact immune system is essential for the full therapeutic benefit of these chemotherapy drugs, as agents like anthracyclines and oxaliplatin trigger ICD to recruit and prime T lymphocytes, turning localized tumor damage into systemic, durable protection. Conversely, T-cell deficiency shifts chemotherapy-induced effects toward immunosuppression; in athymic models, the absence of cytotoxic T-cells leaves tumor-associated macrophages and myeloid-derived suppressor cells unchecked, creating an immunosuppressive microenvironment that directly contributes to underestimation of the therapeutic efficacy which is ultimately used in intact immunity. From our perspective, while athymic nude models remain valuable for direct tumor-cell responses and establishing primary human xenografts, but may underestimate endpoints requiring conventional T-cell priming, effector function, checkpoint interactions, systemic tumor control, or immunological memory. We recommend that preclinical study designs adopt a context-appropriate model strategy pairing athymic models with syngeneic or humanized mouse systems to accurately capture the full therapeutic potential of host-dependent anticancer therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1863372","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:47:12Z","timestamp":1788875232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Athymic murine models can underestimate the immune-dependent components of chemotherapy efficacy"],"prefix":"10.3389","volume":"17","author":[{"given":"Taha Umair","family":"Wani","sequence":"first","affiliation":[{"name":"Department of Pathology, Ilsan Paik Hospital, Inje University College of Medicine","place":["Goyang, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyonok","family":"Yoon","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Gyeongsang National University","place":["Jinju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ye","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ilsan Paik Hospital, Inje University College of Medicine","place":["Goyang, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/jci35180","article-title":"The anticancer immune response: indispensable for therapeutic success","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the immunogenic effects of cancer therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trends Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100224","article-title":"Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade","volume":"3","author":"Kwong","year":"2021","journal-title":"JHEP Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.234","article-title":"Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer","volume":"34","author":"Aranda","year":"2015","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.60","article-title":"Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines","volume":"21","author":"Hannani","year":"2014","journal-title":"Cell Death Differ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2515176","article-title":"Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin","volume":"14","author":"Cerrato","year":"2025","journal-title":"OncoImmunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1417-7","article-title":"Preexisting antitumor immunity augments the antitumor effects of chemotherapy","volume":"62","author":"Zhang","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B12","first-page":"7262","article-title":"Adoptive CD8+ T cell therapy generates immunological memory to inhibit melanoma metastasis","volume":"12","author":"Fu","year":"2020","journal-title":"Am J Trans Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Controlled Release"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int J Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13305","article-title":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model","volume":"108","author":"Shimizu","year":"2017","journal-title":"Cancer Sci"},{"key":"B19","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1085476","article-title":"The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2024.04.032","article-title":"Revealing the nature of Pt-based immunotherapy through the lens of neoantigens in cancer","volume":"69","author":"Xue","year":"2024","journal-title":"Sci Bull"},{"key":"B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-019-0684-0","article-title":"Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response","volume":"11","author":"Mardis","year":"2019","journal-title":"Genome Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.09.010","article-title":"Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy","volume":"68","author":"De Charette","year":"2016","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2018.11.039","article-title":"Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes","volume":"444","author":"Sun","year":"2019","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6908","article-title":"Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol Med Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(94)90013-2","article-title":"Electrochemotherapy\u2014a novel method of cancer treatment","volume":"20","author":"Dev","year":"1994","journal-title":"Cancer Treat Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.18632\/oncotarget.27713","article-title":"Diversifying the platinum-based chemotherapy toolkit for immunogenic cancer cell death","volume":"11","author":"Garg","year":"2020","journal-title":"Oncotarget"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-4598(96)05194-X","article-title":"Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompotent and immunodeficient mice","volume":"43","author":"Sersa","year":"1997","journal-title":"Bioelectrochem Bioenerg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28131","article-title":"Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells","volume":"3","author":"Calvet","year":"2014","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31100478","article-title":"Clinical insights and future prospects: A comprehensive narrative review on immunomodulation induced by electrochemotherapy","volume":"31","author":"Ferioli","year":"2024","journal-title":"Curr Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1336866","article-title":"Electrochemotherapy combined with immunotherapy\u2013a promising potential in the treatment of cancer","volume":"14","author":"Hadzialjevic","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14624","article-title":"Immunogenic chemotherapy in two mouse colon cancer models","volume":"111","author":"Taniura","year":"2020","journal-title":"Cancer Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/or.16.1.141","article-title":"Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide","volume":"16","author":"Motoyoshi","year":"2006","journal-title":"Oncol Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3727\/096504010x12777678141662","article-title":"The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide","volume":"18","author":"Rozados","year":"2010","journal-title":"Oncol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0797-1","article-title":"Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma","volume":"59","author":"Tongu","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2264-3","article-title":"Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation","volume":"68","author":"Amodio","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","article-title":"The role of tumor-associated macrophages in tumor immune evasion","volume":"150","author":"Huang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1331807","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01129","article-title":"Adipocytes and macrophages interplay in the orchestration of tumor microenvironment: new implications in cancer progression","volume":"8","author":"Corr\u00eaa","year":"2017","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1039\/d3nr06333j","article-title":"Macrophage-modulating nanomedicine for cancer immunotherapy","volume":"16","author":"Khan","year":"2024","journal-title":"Nanoscale"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14309","article-title":"Depletion-resistant CD4 T cells enhance thymopoiesis during lymphopenia","volume":"17","author":"Ayasoufi","year":"2017","journal-title":"Am J Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006982","article-title":"Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth","volume":"4","author":"van der Most","year":"2009","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0628-9","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"Van der Most","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939548","article-title":"Induction of peripheral CD4+ T\u2010cell tolerance and CD8+ T\u2010cell cross\u2010tolerance by dendritic cells","volume":"39","author":"Lutz","year":"2009","journal-title":"Eur J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00046","article-title":"The role of CD4+ T follicular helper cells in HIV infection: from the germinal center to the periphery","volume":"8","author":"Thornhill","year":"2017","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1189-x","article-title":"The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues","volume":"61","author":"Tel","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0017-x","article-title":"From checkpoint to checkpoint: DNA damage ATR\/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation","volume":"118","author":"Mouw","year":"2018","journal-title":"Br J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B67","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biomaterials.2016.06.002","article-title":"A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity","volume":"101","author":"He","year":"2016","journal-title":"Biomaterials"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw041","article-title":"Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies","volume":"27","author":"Sanmamed","year":"2016","journal-title":"Ann Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1343-0","article-title":"Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo","volume":"62","author":"Tongu","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.01.040","article-title":"Metronomic chemotherapy and immunotherapy in cancer treatment","volume":"400","author":"Chen","year":"2017","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1863372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:47:14Z","timestamp":1788875234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1863372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1863372"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1863372","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1863372"}}